DiaCarta is using advances in genomics and personalized diagnostics to provide comprehensive cancer patient solutions. Cancer is a genetic disease that is caused by various different driver mutations depending on the cancer type. DiaCarta develops and manufactures precise cancer molecular tests for common mutations seen in the genes NRAS, EGFR and KRAS to facilitate early detection and for recurrence monitoring. The tests use DiaCarta’s proprietary XNA technology allowing sensitive, accurate and cost-effective detection of genetic alterations. This has placed DiaCarta as a leader in the precision diagnostic industry delivering superior clinical performance to healthcare providers and patients.

DiaCarta

Founded: 2007
Location: Richmond, CA
Employee range: 11 - 50
Funding: $45M B Feb 2018; $8M A Jan 2015

Short description:

Drug notes:

Long description:

Jobs: